Status:
COMPLETED
Multi-academic Center Study of Xofigo Patients
Lead Sponsor:
Bayer
Conditions:
Prostate Cancer, Castration Resistant
Eligibility:
MALE
18+ years
Brief Summary
The study will be conducted from a real-world perspective to describe treatment sequences involving radium-223 and chemotherapy in patients with metastatic castrate resistant prostate cancer (mCRPC) a...
Eligibility Criteria
Inclusion
- Received at least one dose of radium-223 after mCRPC diagnosis
- Received at least one prescription or dose of chemotherapy for treatment of mCRPC
Exclusion
- \- No documented visceral metastasis at initiation of radium-223
Key Trial Info
Start Date :
December 3 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 22 2019
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT03419442
Start Date
December 3 2018
End Date
October 22 2019
Last Update
October 22 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bayer US
Whippany, New Jersey, United States, 07981